Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 11:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 308 matching trials from the live ClinicalTrials.gov search.
Conditions
Lymphoma
Interventions
Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Conditions
Influenza
Interventions
H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV), H3N2v inactivated subvirion influenza vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 26 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Rochester, New York
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Open-Label Study of H5 Vaccine in Participants of Protocol 04-077

NCT00402649
Conditions
Influenza
Interventions
Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 10 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
3
States / cities
Torrance, California • Baltimore, Maryland • St Louis, Missouri
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
17
States / cities
Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more
Conditions
Influenza
Interventions
Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Flublok or Fluzone With Advax-CpG55.2 or AF03

NCT03945825
Conditions
Influenza, Influenza Immunisation
Interventions
AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 5 more
Conditions
HIV Infections
Interventions
H1N1 vaccination
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Response to Influenza Vaccine During Pregnancy

NCT03888989
Conditions
Influenza
Interventions
Quadrivalent inactivated influenza vaccine (IIV)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Conditions
Influenza
Interventions
FluMist, Fluzone
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 35 Months
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
3
States / cities
St Louis, Missouri • Cincinnati, Ohio • Nashville, Tennessee
Completed Phase 4 Interventional Accepts healthy volunteers Results available

B-cell Immunity to Influenza (SLVP017)- Year 1, 2009

NCT02133781
Conditions
Influenza
Interventions
Fluzone® 2009-2010 Formula, FluMist® 2009-2010 Formula
Biological
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Stanford, California
Not listed Phase 4 Interventional Accepts healthy volunteers

Effect of Influenza Vaccination on Donor Egg Recipient Outcomes

NCT02946177
Conditions
Infertility, Recurrent Miscarriage
Interventions
Influenza Vaccine, Sterile Saline
Biological · Other
Lead sponsor
Center for Human Reproduction
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Influenza
Interventions
DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

H5 Adult - Chiron Study of Bird Flu Vaccine

NCT00280033
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (Chiron), MF-59, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
4
States / cities
Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more
Conditions
Influenza
Interventions
AS03, Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
7
States / cities
Stanford, California • Decatur, Georgia • Iowa City, Iowa + 3 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Describe the Safety and Immunogenicity of Fluzone®

NCT00524940
Conditions
Influenza
Interventions
Inactivated, Split-Virion Influenza Virus
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Norfolk, Virginia
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

H5 Vaccine Alone or With Adjuvant in Healthy Adults

NCT00296634
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, New York • Durham, North Carolina + 1 more
Completed No phase listed Observational Accepts healthy volunteers

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies

NCT04531787
Conditions
Influenza
Interventions
Influenza vaccine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Recruiting No phase listed Observational Accepts healthy volunteers

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

NCT06029933
Conditions
Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions
Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
1,500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Oakland, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Influence of Chronic CMV Infection on Influenza Vaccine Responses

NCT02134184
Conditions
Cytomegalovirus Infections, Influenza
Interventions
Fluzone® 2012-2013 Formula NDC No 498281-012-50
Biological
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Stanford, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

NCT06038617
Conditions
Fever After Vaccination, Fever, Seizures Fever
Interventions
mRNA COVID-19 Vaccine, Routine Childhood Vaccinations
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Months to 4 Years
Enrollment
347 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
5
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Conditions
Influenza
Interventions
Flublok Quadrivalent influenza vaccine RIV4, Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Up to 64 Years
Enrollment
96,175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Oakland, California
Conditions
Influenza
Interventions
Flucelvax(R), Human Challenge virus
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland